22 July 2024
The second stage of clinical trials for a domestic antitumor drug, developed by scientists from Nazarbayev University, has commenced in Kazakhstan. In the initial stage of the experiment, the drug demonstrated its effectiveness, successfully reducing tumors by an average of 30% in 15 subjects diagnosed with stage four colon cancer. This was announced by the country’s Minister of Science and Higher Education, Sayasat Nurbek.
“By the end of the year we will process all the data. We hope that next year we will launch the medicine for registration,” Nurbek emphasized.
The second stage of the study will involve 3,000 people with various types of cancer, and over 5,000 cancer patients have shown interest in participating in the trial. The tests will take place in Astana, Almaty, and Pavlodar, requiring approximately 2 billion tenge (~370 million rubles) – with the decision on fund allocation having already been made by the Higher Scientific and Technical Commission.
PrintOctober 10 – World Mental Health Day
10 October 2024
Long-Term Game: NovaMedica Experts at the Pharma Marketing Conference
10 October 2024
NovaMedica in the TOP-1000 Russian Managers Rating
28 September 2024
DSM Group predicts the Russian pharmaceutical market will grow by 10% annually
18 October 2024
An extra 6.1 billion rubles will be allocated for drug provision in 2025
18 October 2024
Pharmasyntez to build heparin production plant in Tatarstan
17 October 2024
17 October 2024